The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer
Minsu Park, Eunsun Jung, Jung Min Park, Soeun Park, Dongmi Ko, Juyeon Seo, Seongjae Kim, Kee Dal Nam, Yong Koo Kang, Lee Farrand, Van-Hai Hoang, Cong-Truong Nguyen, Minh Thanh La, Gibeom Nam, Hyunju Park, Jihyae Ann, Jeewoo Lee, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Abstract
Our findings highlight the potent efficacy of HVH-2930 in overcoming trastuzumab resistance in HER2-positive breast cancer. Further investigation is warranted to fully establish its therapeutic potential.
Topics & Concepts
TrastuzumabBreast cancerMedicineCancerInternal medicinePharmacologyOncologyCancer researchHER2/EGFR in Cancer ResearchHeat shock proteins researchToxin Mechanisms and Immunotoxins